Myelolipomas are benign tumors composed of hematopoietic tissue and mature fatty tissue and occur primarily in the adrenal glands. Extra-adrenal sites for these tumors are rare. To date 37 cases have been reported in the literature with more than half of these lesions being presacral in location. The purpose of this report is to raise awareness of this unusual tumor when formulating a differential diagnosis for retroperitoneal tumors. Presacral myelolipomas are easily confused with both primary and secondary malignant retroperitoneal tumors, which are far more common and aggressive neoplasms. Particular radiographic and histologic qualities distinguish this tumor from invasive malignancy. A case report is presented with a review of the literature on extra-adrenal myelolipomas.
Download full-text PDF |
Source |
---|
Surgery
January 2025
Department of Colorectal Surgery, National Cancer Center Hospital, Tokyo, Japan. Electronic address:
Background: A positive pathologic retroperitoneal surgical resection margin in the retroperitonealized colon is reported to predict distant metastases. However, no studies have investigated retroperitoneal surgical resection margin positivity on computed tomography colonography and its prognostic significance.
Methods: Patients who underwent primary resection for ascending or descending colon cancer at our institution between 2013 and 2018 were retrospectively evaluated (n = 206).
Even though Leydig cell tumor (LCT) represents the most common neoplasia among testicular sex cord-stromal tumors (SCSTs), it is a rare condition, comprising 1-2% of all testicular tumors, with a 10% risk of malignancy most commonly located in retroperitoneal lymph nodes. LCTs may demonstrate various clinical manifestations - from asymptomatic intratesticular swelling through nonspecific symptoms such as loss of libido, impotence or infertility, up to feminizing or virilizing syndromes due to hormonal activity of the tumor. This article presents a case of Leydig cell tumor that was associated with azoospermia what have rarely been reported worldwide.
View Article and Find Full Text PDFWorld J Gastrointest Surg
January 2025
Department of Hepatobiliary Surgery, Hunan Provincial People's Hospital (The First Affiliated Hospital of Hunan Normal University), Changsha 410005, Hunan Province, China.
Background: Pancreatic cancer involving the pancreas neck and body often invades the retroperitoneal vessels, making its radical resection challenging. Multimodal treatment strategies, including neoadjuvant therapy, surgery, and postoperative adjuvant therapy, are contributing to a paradigm shift in the treatment of pancreatic cancer. This strategy is also promising in the treatment of pancreatic neck-body cancer.
View Article and Find Full Text PDFFront Oncol
January 2025
Department of Hepatobiliary and Pancreatic Surgery & Retroperitoneal Tumor Surgery, The Affiliated Hospital of Qingdao University, Qingdao, China.
Objective: To evaluate the efficacy and safety of anlotinib combined with envafolimab in the treatment of unresectable or metastatic liposarcoma.
Methods: This single-center, retrospective study enrolled 15 patients with unresectable or metastatic liposarcoma, who were treated at the Retroperitoneal Tumor Surgery Research Center of Qingdao University Affiliated Hospital between April 2022 and November 2023. The treatment regimen consisted of anlotinib combined with envafolimab.
Cureus
December 2024
Internal Medicine, University of Florida College of Medicine, Pensacola, USA.
Extra-adrenal pheochromocytomas are rare neuroendocrine tumors originating outside the adrenal glands and can pose significant diagnostic challenges due to their variable presentations. This report highlights a case of an extra-adrenal pheochromocytoma masquerading as a pancreatic head malignancy. We underscore the importance of considering extra-adrenal pheochromocytoma in the differential diagnosis of pancreatic masses, particularly when biochemical or clinical features suggest catecholamine excess.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!